

Drug toxicity

Edited by J.W. Gorrod

R91
230

London

DRUG TOXICITY

Edited by

J.W. GORROD

Chelsea College
University of London



Y070428



TAYLOR & FRANCIS LTD

10-14 Macklin Street, London WC2B 5NF
1979

First published 1979 by Taylor & Francis Ltd,
10-14 Macklin Street, London WC2B 5NF.

©1979 Taylor & Francis Ltd

All rights reserved. No part of this publication
may be reproduced, stored in a retrieval system
or transmitted, in any form or by any means,
electronic, mechanical, photocopying, recording
or otherwise without the prior permission of the
Copyright owner.

Typeset by Red Lion Setters, Holborn, London
Printed and bound in Great Britain by
Taylor & Francis (Printers) Ltd.
Rankine Road, Basingstoke, Hampshire RG24 0PR

British Library Cataloging in Publication Data

Aspects of Drug Toxicity (*Conference*), London, 1978

Drug Toxicity.

1. Drugs — Toxicology — Congresses

I. Title II. Gorrod, John W

615.9 RA1238

ISBN 0-85066-179-X

Preface

J. W. Gorrod

The material contained in this volume was originally presented at the Pharmaceutical Society's Easter School in April 1978 on Aspects of Drug Toxicity. The lecturers at this school were all experts in their topics, which were chosen to present as wide a view as possible of the contemporary situation of drug toxicity. In a volume of this size, it is not possible to cover every aspect of the subject, but it is hoped that the data presented will enable practising pharmacists and others to assess the likelihood of an adverse reaction having occurred, to propose mechanisms for its initiation, and to suggest means for preventing toxic reactions.

This volume is a sister volume to *Drug Metabolism in Man* and basic data presented in the earlier book have generally been omitted from this one. The first chapter deals with metabolic processes which are available, and for which evidence exists as toxication reactions (Gorrod). This is followed by chapters indicating how these reactions can be modified due to physiological or pharmacological factors. Amongst the topics considered are age (Jondorf), diet (Greaves & McClean), genetics (Boobis). Then follows a chapter on the influence of drug formulation or drug toxicity (Groves). Parke then considers the toxicological consequences produced via enzyme induction or inhibition and Connors deals with the possibility of neoplasia being produced during drug therapy.

Other authors then deal with the effect of drugs and foreign compounds on specific organs or systems. The organs covered are the liver (Slater), the lung (Orme), blood and blood-forming systems (Girdwood), the nervous system (Marsden & Jenner), the foetus (Beck), the optical system (Bron) and the skin (Felix).

Levene presents data which show how chemicals toxic to connective tissue have the potential to be developed into useful drugs. The last chapter deals with untoward effects which may be found during treatment with radiopharmaceuticals (Keeling).

As we live in a world where we are increasingly exposed to small amounts of chemicals in our environment and in our food and drink, the implications of much of this material go far beyond drugs. During the last decade, increasing demands have been made on manufacturers to provide materials

which are 'safe'. It is hoped that this volume will help newcomers to the field of toxicology, in that it provides a broad-based basic text, that nevertheless points to the direction in which toxicology is now rapidly moving.

It is a pleasure to record the encouragement I have received from Professor A. H. Beckett, Head of the School of Pharmacy, Chelsea College, the representatives of the Pharmaceutical Society and the contributors.

It was again a pleasure working with Dr. J. Cheney of Taylor & Francis whose expertise made my lot that much easier.

The contributors to this volume

- F. Beck*, Department of Anatomy, School of Medicine, University of Leicester
- A. R. Boobis*, Department of Clinical Pharmacology, Royal Postgraduate Medical School, London
- A. J. Bron*, Department of Ophthalmology, University of Oxford
- T. A. Connors*, Medical Research Council Toxicology Unit, Carshalton, Surrey
- R.H. Felix*, Frimley Park Hospital, Camberley, Surrey
- R. H. Girdwood*, Department of Therapeutics, School of Medicine, University of Edinburgh
- J. W. Gorrod*, Department of Pharmacy, Chelsea College, London
- M. Angeli-Greaves*, University College Hospital Medical School, London
- M. Groves*, Department of Pharmacy, Chelsea College, London
- P. Jenner*, Institute of Psychiatry, University of London
- W. R. Jondorf*, Racecourse Security Services Laboratories, Newmarket, Suffolk
- D. H. Keeling*, Plymouth General Hospital, Plymouth, Devon
- C. I. Levene*, Department of Pathology, University of Cambridge
- C. D. Marsden*, School of Medicine, King's College, University of London
- A. E. M. McLean*, University College Hospital Medical School, London
- M. Orme*, Department of Pharmacology and Therapeutics, University of Liverpool
- D. V. Parke*, Department of Biochemistry, University of Surrey, Guildford, Surrey
- T. F. Slater*, Department of Biochemistry, Brunel University, Uxbridge, Middlesex

This volume is dedicated to

E. Boyland, D.Sc.

Professor Emeritus of the University of London

*whose recognition of epoxides as active metabolites
paved the way for recent developments
in molecular toxicology*

Contents

<i>Preface</i>		ix	
<i>The contributors to this volume</i>		xi	
Chapter 1	TOXIC PRODUCTS FORMED DURING METABOLISM OF DRUGS AND FOREIGN COMPOUNDS	<i>J. W. Gorrod</i>	1
Introduction			1
Toxic metabolites produced via metabolic attack on carbon			2
Toxic metabolites produced via metabolic attack on constituent nitrogen			10
Toxic metabolites produced via metabolic attack on sulphur			20
Conclusions			22
Chapter 2	DEVELOPMENTAL ASPECTS OF THE METABOLISM AND TOXICITY OF DRUGS	<i>W. R. Jondorf</i>	25
Introduction			25
Mammals			26
Avian species			38
Amphibia			40
Some implications for mammalian developmental pharmacology			44
Chapter 3	GENETIC FACTORS AFFECTING SIDE EFFECTS OF DRUGS	<i>A. R. Boobis</i>	51
Introduction			51
Classification of genetic disorders affecting drug side effects			54
Altered absorption of drugs			55
Altered distribution of drugs			56
Altered metabolism of drugs			57
Altered excretion of drugs			69
Abnormalities in drug response			70
Other drug side effects that may have a genetic basis			81

<i>Chapter 4</i>	THE EFFECT OF DIET ON THE TOXICITY OF DRUGS <i>M. Angeli-Greaves and A. E. M. McLean</i>	91
	Introduction	91
	Pharmacokinetic considerations	92
	Metabolic considerations	92
	Nutrition and toxicity	95
<i>Chapter 5</i>	SIDE EFFECTS CAUSED BY DIFFERENCES IN FORMULATION OF DRUGS <i>M. J. Groves</i>	101
	Introduction	101
	Direct toxicity of formulation adjuvants	102
	Contamination	104
	The sequence of events in drug absorption	105
	The assessment of drug release behaviour from formulations	107
	Examples of drug/formulation interactions	108
	Drug variables which contribute to the variability in response	111
	Formulation variables	111
	The stability of formulations	113
	Sustained drug release formulations	116
	Newer formulations designed to influence activity	119
	Conclusion	120
<i>Chapter 6</i>	FREE RADICAL ASPECTS OF HEPATOTOXICITY <i>T. F. Slater</i>	123
<i>Chapter 7</i>	TOXICOLOGICAL CONSEQUENCES OF ENZYME INDUCTION AND INHIBITION <i>D. V. Parke</i>	133
	Introduction	133
	Differences between drugs and carcinogens as enzyme inducers	135
	Drug interactions due to enzyme inhibition	137
	Drug interactions due to enzyme induction	138
	Effects of enzyme induction and inhibition on toxicity	139
	Enzyme induction in extrahepatic tissues	142
	Long-term drug therapy and folate deficiency	143
	Safrole, enzyme induction and hepatic toxicity	145
	Ligand complexes of cytochrome P-450, enzyme inhibition and toxicity	146

<i>Chapter 8</i>	NEUROLOGICAL TOXICITY OF DRUGS <i>P. Jenner and C. D. Marsden</i>	151
	Introduction	151
	Clinical syndromes of neurotoxicity	152
	Drug-induced neurotoxicity	155
	Predisposing factors to drug-induced neurological disease	157
	Conclusion	158
<i>Chapter 9</i>	THE INDUCTION OF CANCER BY DRUG THERAPY <i>T. A. Connors</i>	161
	Introduction	161
	Cytotoxic agents	163
	Other pharmaceutical agents	173
<i>Chapter 10</i>	TERATOGENESIS PRODUCED BY DRUGS AND RELATED COMPOUNDS <i>F. Beck</i>	179
	Introduction	179
	The analysis of variables in an embryopathic situation	181
	Comparative teratology	185
	The testing of drugs and related compounds for adverse effects upon reproduction	186
	Conclusion	187
<i>Chapter 11</i>	UNWANTED DERMATOLOGICAL RESPONSES DURING DRUG THERAPY <i>R. H. Felix</i>	189
	Introduction	189
	Topical steroids	191
	Antibiotics, antifungal agents and antiseptics combined with topical steroids	195
	Topical antihistamines and anaesthetic agents	197
	Vehicle—bases	198
	Drugs by the systemic route	199
	Investigating adverse drug reactions	210
<i>Chapter 12</i>	THE EFFECTS OF DRUGS AND THEIR METABOLITES ON BLOOD AND BLOOD- FORMING ORGANS <i>R. H. Girdwood</i>	215
	Pancytopenia	215
	Agranulocytosis	218

Thrombocytopenia	218
Haemolytic anaemia	219
Coagulation problems	221
Thrombosis	222
Megaloblastic anaemia	223
Drug-induced vitamin B ₁₂ deficiency	225
Sideroblastic anaemia	225
Leukaemia induced by drugs	225
Drug-induced gastro-intestinal bleeding	225
Methaemoglobinaemia and sulphaemoglobinaemia	225
Porphyria	226
 <i>Chapter 13</i>	
MECHANISMS OF OCULAR TOXICITY	
<i>A. J. Bron</i>	229
Introduction	229
Ocular anatomy and physiology	230
Local toxicity of topical drugs	232
Systemic toxicity of topical drugs	235
The ocular toxicity of systemic drugs	235
Toxic amblyopia	245
Conclusions	251
 <i>Chapter 14</i>	
TOXIC EFFECTS OF COMPOUNDS ON THE PULMONARY SYSTEM	
<i>M. L'E. Orme</i>	255
Introduction	255
Adverse reactions due to drugs	255
Occupational and industrial causes	263
Other materials	265
 <i>Chapter 15</i>	
PROSPECTS FOR THE THERAPEUTIC CONTROL OF FIBROSIS	
<i>C. I. Levene</i>	269
Introduction	269
The structure of collagen	270
Properties of collagen	271
Experimental diseases of collagen	271
Fibrosis	280
Collagen biosynthetic pathway — choice of system	281
 <i>Chapter 16</i>	
SIDE EFFECTS ASSOCIATED WITH THE USE OF RADIOPHARMACEUTICALS	
<i>D. H. Keeling</i>	285
 <i>Index</i>	297

1. Toxic products produced during metabolism of drugs and foreign compounds

J. W. Gorrod

Introduction

In order for a compound to produce a deleterious effect upon a biological system, a reaction between the compound, or a substance derived from it, and a component of the biological system must occur. These reactions may be proximate, i.e. acting at a site directly involved in the advent of the toxic response or they may occur by reacting with a component involved in a sequence of biochemical processes, the disturbance of which precipitates the toxic crisis (Table 1.1). Even within these groups, the nature of the chemical

Table 1.1. Examples of toxicants acting via a direct or indirect reaction within cell.

Toxicant	Reaction	Consequences
<i>Direct reaction</i>		
Cyanide	Complexes with Cytochrome	Block Oxidative Phosphorylation & Respiration
Phenylhydroxylamine	Oxidizes Haemoglobin	Prevents Oxygen Transport
Fluorocitrate	Inhibits Aconitase	Blocks T.C.A Cycle
6-Aminonicotinamide	Forms analogues of coenzymes	Blocks Pentose Pathway
<i>Indirect reaction</i>		
Silica	Absorbed into lysosomes	Releases hydrolytic enzymes
Free Radicals	React with lipids	Initiate lipid peroxidation
Mercurials	React with thiols	Removes protection and upsets cell oxidn/redn. potential

reaction is often poorly defined and whilst in many cases evidence has been obtained for the formation of covalent bonds between toxicants and cellular constituents, this is by no means a prerequisite for a toxic response. In other cases, reaction via an ionic band or a charge-transfer complex may play a role in initiating an adverse response to a drug. Thus the ability of a compound to react with an enzyme or a membrane or a discrete molecule may arise by several mechanisms.

The nature of the bond formed is important in determining the duration

of the compounds within the body; in certain cases the bond may be easily destroyed, as in the dissociation of certain inhibitors from enzymes or by hydrolysis, as in the breakdown of Schiff bases. The alternative situation may occur where the covalent bond formed between a toxicant and a macromolecule is extremely stable and only excision of the affected portion of molecule allows the release of the toxicant.

While the majority of compounds which are able to produce toxic effects require metabolism in order to produce a more reactive molecule, this is not always the case, and many molecules which are used in human therapy possess an inherent reactivity which allows reaction with cellular components. Examples of this type include various alkylating agents, including those based on strained rings, cyclic lactones and lactams. Some structures of this type of reactive compound are shown in Figure 1.1. This reactivity may enable drugs to produce antigenic material by reaction with protein and thereby produce an unwanted immunological response (Erlanger, 1973).




Fig. 1.1. Examples of chemically reactive drugs (a) sulphur mustards, (b) nitrogen mustards, (c) methylsulphonyl esters, (d) propiolactone, (e) ethylene oxide, (f) ethyleneimines, (g) thalidomide, (h) penicillanic acid.

Most of the toxic compounds to which we are exposed consist of carbon in combination with a hetero atom, usually oxygen, nitrogen or sulphur, and during metabolism either the carbon, nitrogen or sulphur is attacked. It is worth considering toxic metabolites produced by these processes separately.

Toxic metabolites produced via metabolic attack on carbon

Due to the potent carcinogenic properties of a number of polycyclic aromatic hydrocarbons, this group of compounds have been extensively studied over nearly half a century, Kennaway (1930) having isolated and characterized the first pure carcinogens as aromatic hydrocarbons. It was early recognized the dihydrodiols were formed as metabolites of aromatic hydrocarbons (Boyland & Levi, 1935; Young, 1947; Boyland & Wolf,

1950), a fact that led Boyland (1950) to suggest that aryl epoxides were intermediates in the metabolism of hydrocarbons. It was not until the successful synthesis of this type of compound had been accomplished by Newman & Blum (1964) that aryl epoxides were shown to exist; this ultimately led to the direct detection of naphthalene-1,2-epoxide as a metabolite of naphthalene by Jerina *et al.* (1968).

Aryl epoxides, as predicted by Boyland, are compounds capable of several reactions; these are exemplified in Figure 1.2. Aryl epoxides can isomerize to give phenols, the phenol formed depending upon the electron density of the carbon atoms involved, they can react with water, as substrates for the enzyme epoxide hydrase, or they can react with nucleophiles.




Fig. 1.2. Metabolism of naphthalene.

Figure 1.2 shows reaction with glutathione, and this type of reaction is thought to occur when epoxides react with cellular macromolecules of protein, DNA or RNA. *In vivo* glutathione conjugates are ultimately excreted as mercapturic acids. Aryl epoxides can also be reduced to the parent hydrocarbon. The role of epoxides in aromatic hydrocarbon metabolism and carcinogenesis has been reviewed by Sims & Grover (1974).

The role of epoxides in hydrocarbon metabolism becomes even more complicated when one considers the number of possible sites available for epoxidation in the larger molecules which are of major toxicological interest. An example of this complexity is indicated in Figure 1.3, which shows the three primary sites of oxidation of benzantracene. These epoxides, viz. 5:6, 8:9 and 10:11, all react with water to form dihydrodiols as well as form analogous products as described for naphthalene earlier. There have been many attempts to correlate the site of oxidation within the hydrocarbon with the initiation of carcinogenesis, the most widely accepted being the K region hypothesis (Pullman & Pullman, 1955). However there were always anomalies and it was a major breakthrough when Swaisland *et al.* (1974) established that further epoxidation of 8,9-dihydro-8,9-dihydroxybenzantracene was involved in the reaction of the parent hydrocarbon with nucleic acids (Figure 1.3). A similar reaction was observed with benzyrene (Sims *et al.*, 1974). These diol-epoxides which are produced are also substrates for epoxide hydrase, being converted to tetrahydrotetrols (Figure 1.3). Many diol-epoxides are now known to be intermediates in the reaction of hydrocarbons with nucleic acids. From Figure 1.3 it can be seen that several diol-epoxides could be formed from each hydrocarbon, and while this may be the case, it appears that epoxidation of a double bond in a





Fig. 1.3. Metabolism of benzantracene.

diol-containing ring which is adjacent to a 'bay' in the molecule (indicated  in Figure 1.4) produces the most reactive metabolite.

From a consideration of the data on the carcinogenicity of substituted hydrocarbons and quantum mechanical calculations, a theory has been developed predicting that bay region epoxides derived from non-K-region dihydrodiols would have the highest biological activity (Jerina & Daly, 1977; Jerina *et al.*, 1977). Further examples of diol-epoxides derived from carcinogenic hydrocarbons are shown in Figure 1.4.

Epoxidation as a toxication process is not restricted to aromatic hydrocarbons and it has been suggested that they are formed during the metabolism of safrole (Figure 1.5A). In the case of this weak carcinogen, it is not certain whether hydroxylation of the methylene carbon is also required to produce the proximate carcinogen (Stilwell *et al.*, 1974). Aflatoxin B₁, which is a potent naturally occurring carcinogen, is also thought to be activated via epoxidation of the distal furan ring (Figure 1.5B) (Swenson, Miller & Miller, 1974). Epoxidation may also be involved in the toxic effects produced by vinyl chloride.

From the foregoing it might be presumed that epoxidation was always associated with enhanced toxicity. However, studies using epoxides known to be formed as metabolites of carbamazepine, cyproheptadine and cyclobenzaprine (Figure 1.6) showed that they were fully devoid of mutagenic activity when tested in systems capable of detecting either frameshift or




Fig. 1.4 Conversion of (a) 7-methylbenzanthracene, (b) 7, 12 dimethylbenzanthracene, (c) benzpyrene, (d) methylcholanthrene, to 'bay region' epoxides.




Fig. 1.5 Metabolism of (A) safrole and (B) of aflatoxin to form epoxides.




Fig. 1.6. Epoxidation of drugs containing an aliphatic double band.

base substitution mutagens (Glatt *et al.*, 1975). Indeed, studies on the metabolism of the hepatotoxic agent bromobenzene (Figure 1.7) (Jollow & Smith, 1977) suggest that whereas pretreatment of experimental animals with phenobarbitone produces more bromobenzene-3,4-epoxide, leading to enhanced toxicity, pretreatment with methylcholanthrene leads to more 2,3-epoxide, leading to diminished toxicity as the toxic 3,4-epoxide is formed in




Fig. 1.7. Possible metabolic conversion of bromobenzene to two different epoxides.

lower amounts. Clearly epoxidation can be a reaction which is involved in producing a toxic effect. However, the variety of further reactions which epoxides can undergo (Figure 1.2) and the rate at which these reactions proceed, will determine the role of epoxides in the metabolism and toxicity of any molecule. As the site of epoxidation and the properties of the epoxide formed are dependent upon the electron distribution within the molecule and the activity of the various P-450-type cytochromes and the environment within which they are formed, it may be that in many cases the potential toxic effect is never realized or only manifests itself under certain conditions.